Fig. 6

Neurogenesis and cell proliferation as assessed by DCX and BrdU immunohistochemistry in mice maintained on control (CTL) or high-fat diets (HFD) and treated with vehicle (Veh) or the TLR4 inhibitor, TAK-242 (TAK). a–d Representative images of DCX immunohistochemistry in mice treated with a control diet (CTL) and vehicle (Veh), b control diet and TAK-242 (TAK), c high-fat diet (HFD) and vehicle, and d high-fat diet and TAK-242. Scale bar = 50 μm. e Densities of DCX immunoreactive cells were quantified in the dentate gyrus. f The maturation state of DCX-positive cells was assessed, and cells were categorized as type 1, type 2, or type 3 based on their dendritic morphology. g BrdU-positive cells were quantified in the dentate gyrus. Data are presented as mean (±SEM) values; n = 10/group. Vehicle-treated animals are shown in white bars, and TAK-242-treated are shown in black bars; for DCX morphology, CTL diet-fed animals are shown in solid bars and HFD-fed animals are shown in striped bars. Statistical significance is based on ANOVA followed by Bonferroni correction. #p < 0.05 relative to vehicle-treated mice in the same diet condition